KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Work In Process (2016 - 2020)

Historic Work In Process for Amgen (AMGN) over the last 5 years, with Q1 2020 value amounting to $2.2 billion.

  • Amgen's Work In Process rose 2384.18% to $2.2 billion in Q1 2020 from the same period last year, while for Mar 2020 it was $2.2 billion, marking a year-over-year increase of 2384.18%. This contributed to the annual value of $2.2 billion for FY2019, which is 3415.66% up from last year.
  • Amgen's Work In Process amounted to $2.2 billion in Q1 2020, which was up 2384.18% from $2.2 billion recorded in Q4 2019.
  • Over the past 5 years, Amgen's Work In Process peaked at $2.2 billion during Q4 2019, and registered a low of $1.5 billion during Q1 2017.
  • Its 5-year average for Work In Process is $1.8 billion, with a median of $1.7 billion in 2018.
  • In the last 5 years, Amgen's Work In Process crashed by 47.96% in 2018 and then skyrocketed by 3415.66% in 2019.
  • Over the past 5 years, Amgen's Work In Process (Quarter) stood at $1.6 billion in 2016, then rose by 3.73% to $1.7 billion in 2017, then decreased by 0.48% to $1.7 billion in 2018, then skyrocketed by 34.16% to $2.2 billion in 2019, then decreased by 1.57% to $2.2 billion in 2020.
  • Its Work In Process stands at $2.2 billion for Q1 2020, versus $2.2 billion for Q4 2019 and $1.9 billion for Q3 2019.